⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Complement 3 Glomerulopathy (C3G) Market Analysis Report 2026-2036 | Complement 3 Glomerulopathy Market Forecast to Reach Approximately $1 Billion by 2036 as Targeted Therapies Transform C3G Treatment
globenewswire.com
NVS
APLS
NVO
OMER
ARWR
2026 RNAi Therapeutics Market Report (3rd Edition): Analysis by Type of RNAi Molecule, Therapeutic Area, Route of Administration, Key Geographical Regions, Sales Forecast and Leading Industry Players to 2035
globenewswire.com
ALNY
ARWR
NVO
NVS
BIIB
REGN
GILD
MRK
BMY
ABBV
AMGN
AZN
PFE
SNY
TEVA
BHC
CRSP
EDIT
NTLA
SRPT
SLN
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
businesswire.com
ARWR
2026 RNAi Drug Delivery Market Report: Global Revenues to Reach $3.34 Billion by 2031, Driven by siRNA Approvals and Delivery Platform Innovation
globenewswire.com
ALNY
ARWR
ABUS
PFE
AZN
IONS
MRK
NVO
ROG
SNY
SLN
TAK
Nanomedicine Market Report Examines Products, Services and Growth Opportunities Through 2030
globenewswire.com
ABT
ARWR
BMY
GEHC
GILD
INV
JNJ
TMO
MRK
NVS
PFE
TEVA
Form 8-K
sec.gov
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
businesswire.com
ARWR
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
businesswire.com
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
businesswire.com
ARWR
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
businesswire.com
ARWR